Evidence map›Paper›PMID 40687950›Full record

ArticleThe journal of allergy and clinical immunology. Global2025

Independent association of a 17q21 variant with exacerbations in type 2-low adult asthma.

Yumi Ishiyama, Hisako Matsumoto, Hironobu Sunadome, Yuji Tohda, Takahiko Horiguchi, Hideo Kita, Kazunobu Kuwabara, Keisuke Tomii, Kojiro Otsuka, Masaki Fujimura and 23 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of allergy and clinical immunology. Global, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Yumi IshiyamaDepartment of Respiratory Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Hisako MatsumotoDepartment of Respiratory Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Hironobu SunadomeDepartment of Respiratory Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Yuji TohdaKindai University Hospital, Osaka, Japan.
Takahiko HoriguchiDepartment of Respiratory Internal Medicine, Fujita Health University Second Educational Hospital, Toyoake, Japan.
Hideo KitaDepartment of Respiratory Medicine, Takatsuki Red Cross Hospital, Osaka, Japan.
Kazunobu KuwabaraDepartment of Internal Medicine/Respiratory Medicine, Fujita Health University School of Medicine, Nagoya, Japan.
Keisuke TomiiDepartment of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan.
Kojiro OtsukaDepartment of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan.
Masaki FujimuraDepartment of Respiratory Medicine, Cellular Transplantation Biology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.
Noriyuki OhkuraDepartment of Respiratory Medicine, Cellular Transplantation Biology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.
Katsuyuki TomitaDepartment of Respiratory Medicine and Allergology, Faculty of Medicine, Kinki University, Osaka, Japan.
Akihito YokoyamaDepartment of Respiratory Medicine and Allergology, Kochi Medical School Kochi University, Kochi, Japan.
Hiroshi OhnishiDepartment of Respiratory Medicine and Allergology, Kochi Medical School Kochi University, Kochi, Japan.
Yasutaka NakanoDivision of Respiratory Medicine, Department of Internal Medicine, Shiga University of Medical Science, Otsu, Japan.
Tetsuya OgumaDivision of Respiratory Medicine, Department of Internal Medicine, Shiga University of Medical Science, Otsu, Japan.
Soichiro HozawaDepartment of Respiratory Medicine, Hiroshima Allergy and Respiratory Clinic, Hiroshima, Japan.
Yoshihiro KanemitsuDepartment of Respiratory Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Tadao NagasakiDepartment of Respiratory Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Isao ItoDepartment of Respiratory Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Tsuyoshi OgumaDepartment of Respiratory Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Hideki InoueDepartment of Respiratory Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Tomoko TajiriDepartment of Respiratory Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Toshiyuki IwataDepartment of Respiratory Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Junya OnoShino-Test Corp, Sagamihara, Japan.
Shoichiro OhtaDepartment of Laboratory Medicine, Saga Medical School, Saga, Japan.
Tomomitsu HirotaDivision of Molecular Genetics, Research Center for Medical Science, The Jikei University School of Medicine, Tokyo, Japan.
Mayumi TamariDivision of Molecular Genetics, Research Center for Medical Science, The Jikei University School of Medicine, Tokyo, Japan.
Akio NiimiDepartment of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University School of Medical Sciences, Nagoya, Japan.
Kenji IzuharaDivision of Allergy, Department of Biomolecular Sciences, Saga Medical School, Saga, Japan.
Michiaki MishimaDepartment of Respiratory Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Toyohiro HiraiDepartment of Respiratory Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Kinki Hokuriku Airway disease Conference (KiHAC) Study

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The genetic factors contributing to exacerbations in type 2-low asthma are not well understood. Objective: We sought to clarify the association between variants in gasdermin B/orosomucoid-like 3 ( Methods: This follow-up study of the multicenter Kinki Hokuriku Airway disease Conference (KiHAC) enrolled adults with asthma who were receiving inhaled corticosteroids. It examined associations between asthma exacerbations requiring systemic corticosteroids over 2 years and clinical and genetic factors in patients with the type 2-low endo-genotype, defined by serum periostin levels lower than 95 ng/mL and the Results: A total of 115 patients with the type 2-low endo-genotype were analyzed (mean age, 62 years; 76.5% female). During the 2-year follow-up, 32 patients experienced 1 or more exacerbation. Multivariate analysis identified the rs7216389 TT genotype, recent exacerbations, female sex, and higher body mass index as independent risk factors for asthma exacerbations in patients with the type 2-low endo-genotype. The association between the rs7216389 TT genotype and exacerbations was confirmed in patients with the type 2-low genotype in the KiHAC (n = 89) and replication (n = 125) cohorts. Conclusions: The rs7216389 TT variant on 17q21 may be an independent risk factor for exacerbations in adults with type 2-low asthma, highlighting the role of

Indexed as

17q21asthma exacerbationGSDMBORMDL3rs7216389Type 2–low asthma

Identifiers

PMID40687950
PMCPMC12271856

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.